688189 南新制药
已收盘 03-13 15:00:00
资讯
新帖
简况
一年狂卖8亿元的流感创新药“失宠”,拿4.8亿元并购却惨遭打脸,南新制药扭亏困局何解?
华夏时报网 · 03-11
一年狂卖8亿元的流感创新药“失宠”,拿4.8亿元并购却惨遭打脸,南新制药扭亏困局何解?
每周股票复盘:南新制药(688189)回购股份211.8万股
证券之星 · 03-08
每周股票复盘:南新制药(688189)回购股份211.8万股
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,3月2日股价下跌5.06%
证券之星 · 03-02
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,3月2日股价下跌5.06%
每周股票复盘:南新制药(688189)2025年净亏1.372亿元
证券之星 · 03-01
每周股票复盘:南新制药(688189)2025年净亏1.372亿元
南新制药发布2025年度业绩快报,亏损1.372亿元
证券之星 · 02-27
南新制药发布2025年度业绩快报,亏损1.372亿元
“骨折价”出清坏账,南新制药业绩亏损、转型困境待解
新京报 · 02-12
“骨折价”出清坏账,南新制药业绩亏损、转型困境待解
股市必读:南新制药(688189)预计2025年全年营业收入1.2亿元至1.5亿元
证券之星 · 02-02
股市必读:南新制药(688189)预计2025年全年营业收入1.2亿元至1.5亿元
每周股票复盘:南新制药(688189)2025年预亏1.2亿至1.6亿元
证券之星 · 02-01
每周股票复盘:南新制药(688189)2025年预亏1.2亿至1.6亿元
南新制药(688189)披露2025年年度业绩预亏公告,1月30日股价下跌0.12%
证券之星 · 01-30
南新制药(688189)披露2025年年度业绩预亏公告,1月30日股价下跌0.12%
南新制药(688189)披露关于持股5%以上股东减持计划时间届满暨减持结果公告,1月26日股价上涨1.9%
证券之星 · 01-26
南新制药(688189)披露关于持股5%以上股东减持计划时间届满暨减持结果公告,1月26日股价上涨1.9%
每周股票复盘:南新制药(688189)累计回购股份1,910,214股
证券之星 · 01-11
每周股票复盘:南新制药(688189)累计回购股份1,910,214股
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,01月05日股价上涨6.27%
证券之星 · 01-05
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,01月05日股价上涨6.27%
南新制药(688189)披露2025年第二次临时股东会决议公告,12月29日股价上涨0.12%
证券之星 · 2025-12-29
南新制药(688189)披露2025年第二次临时股东会决议公告,12月29日股价上涨0.12%
每周股票复盘:南新制药(688189)股东会通过变更会计师事务所
证券之星 · 2025-12-28
每周股票复盘:南新制药(688189)股东会通过变更会计师事务所
南新制药完成董事会换届并变更会计师事务所
中金财经 · 2025-12-27
南新制药完成董事会换届并变更会计师事务所
南新制药拟变更2025年度审计机构为华兴会计师事务所
中金财经 · 2025-12-11
南新制药拟变更2025年度审计机构为华兴会计师事务所
南新制药股份回购比例达1%
证券日报 · 2025-12-10
南新制药股份回购比例达1%
兴业证券:26Q2预计家电外销景气优于内销 推荐石头科技(688189.SH)等
智通财经 · 2025-12-10
兴业证券:26Q2预计家电外销景气优于内销 推荐石头科技(688189.SH)等
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,12月1日股价下跌2.01%
证券之星 · 2025-12-01
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,12月1日股价下跌2.01%
南新制药前三季度亏损扩大,公司面临被监管立案等多重困境
中科财经 · 2025-11-14
南新制药前三季度亏损扩大,公司面临被监管立案等多重困境
公司概况
公司名称:
湖南南新制药股份有限公司
所属行业:
医药制造业
上市日期:
2020-03-26
主营业务:
湖南南新制药股份有限公司的主营业务是流行性感冒等抗病毒、传染病防治药品,以及恶性肿瘤、心脑血管疾病、糖尿病等其他重大疾病治疗药品研发、生产与销售。公司的主要产品是帕拉米韦氯化钠注射液、磷酸奥司他韦干混悬剂、辛伐他汀分散片、阿托伐他汀钙片、贝那普利氢氯噻嗪片、头孢呋辛酯分散片、头孢克洛胶囊、头孢克洛干混悬剂、乳酸环丙沙星氯化钠注射液、复方布洛芬片、布洛芬混悬滴剂、布洛芬混悬液、盐酸非索非那定口服混悬液。
发行价格:
34.94
{"stockData":{"symbol":"688189","market":"SH","secType":"STK","nameCN":"南新制药","latestPrice":7.94,"timestamp":1773385200000,"preClose":7.99,"halted":0,"volume":3661407,"delay":0,"changeRate":-0.0063,"floatShares":274000000,"shares":274000000,"eps":-1.3423,"marketStatus":"已收盘","change":-0.05,"latestTime":"03-13 15:00:00","open":7.93,"high":8.08,"low":7.88,"amount":29230000,"amplitude":0.025,"askPrice":7.96,"askSize":48,"bidPrice":7.94,"bidSize":85,"shortable":0,"etf":0,"ttmEps":-1.3423,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":5,"adr":0,"adjPreClose":7.99,"symbolType":"stock_kcb","openAndCloseTimeList":[[1773365400000,1773372600000],[1773378000000,1773385200000]],"highLimit":8.79,"lowLimit":7.19,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":274400000,"isCdr":false,"pbRate":2.52,"roa":"--","roe":"--","epsLYR":-1.3007,"committee":0.098243,"marketValue":2179000000,"turnoverRate":0.0133,"status":1,"afterMarket":{"amount":0,"volume":0,"close":7.94,"buyVolume":0,"sellVolume":0,"time":1773387237558,"indexStatus":"已收盘 03-13 15:30:00","preClose":7.99},"floatMarketCap":2179000000},"requestUrl":"/m/hq/s/688189/wiki","defaultTab":"wiki","newsList":[{"id":"2618443489","title":"一年狂卖8亿元的流感创新药“失宠”,拿4.8亿元并购却惨遭打脸,南新制药扭亏困局何解?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618443489","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618443489?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:26","pubTimestamp":1773228360,"startTime":"0","endTime":"0","summary":" 作为曾凭抗流感创新药成名的科创板药企,南新制药(维权)近日披露2025年度业绩快报。截至2025年4月,国内帕拉米韦注射液相关批文为32个,涉及多家知名药企,直接挤压了南新制药的市场空间。 并购折戟的同时,南新制药的资金压力持续凸显。 不仅如此,因涉嫌年报信息披露违法违规,南新制药于2025年9月30日收到中国证监会《立案告知书》,目前调查仍在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-11/doc-inhqrmmk2505340.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-11/doc-inhqrmmk2505340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","159992","BK1161","06978","BK1574","688189"],"gpt_icon":0},{"id":"2617663695","title":"每周股票复盘:南新制药(688189)回购股份211.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663695","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663695?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:18","pubTimestamp":1772911092,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,南新制药报收于8.15元,较上周的8.5元下跌4.12%。本周,南新制药3月2日盘中最高价报8.44元。本周关注点公司公告汇总:截至2026年2月28日,公司累计回购股份2,118,214股,占公司总股本的0.77%。截至2026年2月28日,公司累计回购股份2,118,214股,占公司总股本的0.77%,已支付资金总额17,918,614.54元,回购价格区间为7.02元/股至8.92元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2616359504","title":"南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,3月2日股价下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616359504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616359504?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:33","pubTimestamp":1772465591,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,南新制药报收于8.07元,较前一交易日下跌5.06%,最新总市值为22.14亿元。近日,湖南南新制药股份有限公司披露《关于以集中竞价交易方式回购公司股份的进展公告》。公告显示,公司于2025年4月28日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购资金总额不低于1,000万元且不超过2,000万元,回购价格不超过9.53元/股,回购期限为12个月,自2025年4月28日至2026年4月27日,拟用于员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2616845423","title":"每周股票复盘:南新制药(688189)2025年净亏1.372亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616845423","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616845423?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:59","pubTimestamp":1772305148,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,南新制药报收于8.5元,较上周的8.48元上涨0.24%。本周,南新制药2月25日盘中最高价报8.75元。本周关注点来自业绩披露要点:南新制药2025年归属净利润亏损1.372亿元,同比减亏61.54%。公司公告汇总湖南南新制药股份有限公司发布2025年度业绩快报,报告期内实现营业总收入14,192.76万元,同比下降46.09%;营业利润为-13,250.69万元,利润总额为-13,267.37万元,归属于母公司所有者的净利润为-13,724.83万元,亏损幅度较上年大幅减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2614283589","title":"南新制药发布2025年度业绩快报,亏损1.372亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614283589","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614283589?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:17","pubTimestamp":1772183823,"startTime":"0","endTime":"0","summary":"证券之星消息,南新制药近日即将发布2025年年报,根据2月27日发布的业绩快报,归属净利润亏损1.372亿元,同比增长61.54%。报告期内,公司实现营业收入 14,192.76 万元,比上年同期减少 46.09%;实现营业利润-13,250.69 万元,实现利润总额-13,267.37万元,实现归属于母公司所有者的净利润-13,724.83 万元。报告期内,受国内医药行业集中采购等政策深入推进、同类竞品不断上市等因素影响,市场竞争加剧,加之 2025 年前三季度国内流感较少,导致公司营业收入和毛利率均有所下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700028481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2610941781","title":"“骨折价”出清坏账,南新制药业绩亏损、转型困境待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2610941781","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610941781?lang=zh_cn&edition=full","pubTime":"2026-02-12 18:13","pubTimestamp":1770891180,"startTime":"0","endTime":"0","summary":"南新制药试图通过清理存量资产缓解经营压力,在这个看似常规的财务操作背后,是南新制药持续亏损、转型屡屡受挫、内控与监管承压的多重困境。2025年前三季度,经营状况进一步恶化,南新制药实现营业总收入8315.44万元,同比下降66.89%;归母净利润亏损6863.38万元,较上年同期亏损额进一步增加。自2020年后,南新制药便未在年报中单独披露帕拉米韦的销售收入。","market":"hk","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262121715582908595.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262121715582908595.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1770891220169990.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1770891220169990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2608814128","title":"股市必读:南新制药(688189)预计2025年全年营业收入1.2亿元至1.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608814128","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608814128?lang=zh_cn&edition=full","pubTime":"2026-02-02 04:44","pubTimestamp":1769978651,"startTime":"0","endTime":"0","summary":"业绩披露要点业绩预告南新制药发布业绩预告,预计2025年全年扣除后营业收入为11,990万元至14,990万元;预计全年营业收入为1.2亿元至1.5亿元;扣非后净利润亏损1.25亿元至1.65亿元;归属净利润亏损1.2亿元至1.6亿元。公司公告汇总2025年年度业绩预亏公告湖南南新制药股份有限公司预计2025年年度实现营业收入12,000.00万元到15,000.00万元,同比减少43.03%到54.42%;扣除与主营业务无关的收入后为11,990.00万元到14,990.00万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189"],"gpt_icon":0},{"id":"2608703780","title":"每周股票复盘:南新制药(688189)2025年预亏1.2亿至1.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608703780","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608703780?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:55","pubTimestamp":1769889309,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,南新制药报收于8.45元,较上周的8.93元下跌5.38%。本周,南新制药1月27日盘中最高价报9.15元。业绩披露要点南新制药发布业绩预告,预计2025年全年归属净利润亏损1.2亿元至1.6亿元。预计全年营业收入为1.2亿元至1.5亿元,同比减少43.03%到54.42%。扣除与主营业务无关的收入后,营业收入为1.199亿元至1.499亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2607042267","title":"南新制药(688189)披露2025年年度业绩预亏公告,1月30日股价下跌0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607042267","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607042267?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:30","pubTimestamp":1769787026,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,南新制药报收于8.45元,较前一交易日下跌0.12%,最新总市值为23.19亿元。该股当日开盘8.46元,最高8.58元,最低8.34元,成交额达4006.53万元,换手率为1.73%。近日,湖南南新制药股份有限公司发布2025年年度业绩预亏公告。公告显示,公司预计2025年年度实现营业收入12,000.00万元到15,000.00万元,同比减少43.03%到54.42%;扣除与主营业务无关的收入后为11,990.00万元到14,990.00万元。归属于母公司所有者的净利润预计为-16,000.00万元到-12,000.00万元,亏损同比减少55.17%到66.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2606249300","title":"南新制药(688189)披露关于持股5%以上股东减持计划时间届满暨减持结果公告,1月26日股价上涨1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606249300","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606249300?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:43","pubTimestamp":1769438610,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘,南新制药报收于9.1元,较前一交易日上涨1.9%,最新总市值为24.97亿元。近日,南新制药发布《关于持股5%以上股东减持计划时间届满暨减持结果公告》。截至2026年1月26日,广州乾元未实施减持,减持计划期限届满,仍持有公司股份43,120,000股,持股比例为15.71%。本次减持未违反相关法律法规及前期承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600036568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2602653665","title":"每周股票复盘:南新制药(688189)累计回购股份1,910,214股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602653665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602653665?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:52","pubTimestamp":1768074755,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,南新制药报收于8.87元,较上周的7.97元上涨11.29%。本周,南新制药1月9日盘中最高价报8.92元。公司公告汇总:公司累计回购股份1,910,214股,占总股本0.70%,已支付资金16,138,029.08元。2025年12月单月回购952,194股,支付资金8,140,181.25元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2601000437","title":"南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,01月05日股价上涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000437","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000437?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:27","pubTimestamp":1767608832,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,南新制药报收于8.47元,较前一交易日上涨6.27%,最新总市值为23.24亿元。公司近日发布《关于以集中竞价交易方式回购公司股份的进展公告》。公告显示,湖南南新制药股份有限公司于2025年4月28日召开董事会,审议通过以集中竞价交易方式回购股份的方案,回购资金总额预计为1,000万元至2,000万元,用于员工持股计划或股权激励,回购价格不超过9.53元/股,实施期限为2025年4月28日至2026年4月27日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500028928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2595786733","title":"南新制药(688189)披露2025年第二次临时股东会决议公告,12月29日股价上涨0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595786733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595786733?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:46","pubTimestamp":1767001575,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘,南新制药报收于8.05元,较前一交易日上涨0.12%,最新总市值为22.09亿元。该股当日开盘8.02元,最高8.13元,最低7.98元,成交额达3513.61万元,换手率为1.59%。近日,湖南南新制药股份有限公司发布2025年第二次临时股东会决议公告。公告显示,公司于2025年12月26日召开2025年第二次临时股东会,审议通过了《关于变更会计师事务所的议案》及选举第二届董事会非独立董事的议案。出席会议股东84人,代表表决权45.4364%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900024472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2594255242","title":"每周股票复盘:南新制药(688189)股东会通过变更会计师事务所","url":"https://stock-news.laohu8.com/highlight/detail?id=2594255242","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594255242?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:22","pubTimestamp":1766866931,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,南新制药报收于8.04元,较上周的8.27元下跌2.78%。本周,南新制药12月22日盘中最高价报8.35元。本周关注点公司公告汇总:南新制药2025年第二次临时股东会审议通过变更会计师事务所议案,获99.5168%同意票。出席会议股东84人,代表表决权45.4364%。北京大成(广州)律师事务所见证会议并出具法律意见书,认为会议程序及表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2594688219","title":"南新制药完成董事会换届并变更会计师事务所","url":"https://stock-news.laohu8.com/highlight/detail?id=2594688219","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594688219?lang=zh_cn&edition=full","pubTime":"2025-12-27 08:34","pubTimestamp":1766795679,"startTime":"0","endTime":"0","summary":"中访网数据 湖南南新制药股份有限公司于2025年12月26日召开了2025年第二次临时股东会。会议审议并通过了《关于变更会计师事务所的议案》,该议案获得了超过99.5%的同意票。同时,会议以累积投票方式选举产生了第二届董事会部分非独立董事,张平丽、刘勇兵均以超过98.7%的得票率当选。此次股东会决议标志着南新制药在完善公司治理结构方面迈出了新的一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251227/31895866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2590056923","title":"南新制药拟变更2025年度审计机构为华兴会计师事务所","url":"https://stock-news.laohu8.com/highlight/detail?id=2590056923","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590056923?lang=zh_cn&edition=full","pubTime":"2025-12-11 12:46","pubTimestamp":1765428372,"startTime":"0","endTime":"0","summary":"中访网数据 湖南南新制药股份有限公司于2025年12月10日召开董事会,审议通过变更2025年度审计机构的议案。公司拟聘任华兴会计师事务所(特殊普通合伙)担任2025年度财务报告及内部控制审计机构,以替代原审计机构大华会计师事务所(特殊普通合伙)。此次变更主要基于公司业务发展及审计服务需求,旨在确保年度审计工作的顺利开展。华兴会计师事务所2024年度审计业务收入为35,599.98万元,具备为上市公司提供审计服务的专业能力。本次审计费用总额为213万元,较上年度增加6万元。公司已就变更事宜与前后任会计师事务所进行沟通,双方均无异议。该议案尚需提交公司股东大会审议批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251211/31858805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2590358298","title":"南新制药股份回购比例达1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590358298","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590358298?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:11","pubTimestamp":1765368660,"startTime":"0","endTime":"0","summary":"本报讯 12月10日晚间,湖南南新制药(维权)股份有限公司公告,截至2025年12月10日,公司通过集中竞价交易方式累计回购股份约274.4万股,占公司总股本的1.00%。 未来,南新制药将继续严格遵循相关法律法规,根据市场情况择机推进后续回购工作,同时持续聚焦主业发展,提升核心竞争力与盈利能力,以优异的经营业绩回报广大投资者、赋能员工成长、助力行业进步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-10/doc-inhaiqhy9779468.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-10/doc-inhaiqhy9779468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2590743383","title":"兴业证券:26Q2预计家电外销景气优于内销 推荐石头科技(688189.SH)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2590743383","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590743383?lang=zh_cn&edition=full","pubTime":"2025-12-10 10:34","pubTimestamp":1765334084,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,兴业证券发布研报称,展望2026年,考虑国补退坡及高基数,预计家电内销有所承压,趋势上前低后高;26Q2起外销进入较低基数区间,叠加关税影响逐步缓和、美联储降息预期催化、欧美需求修复与新兴市场高增兑现,预计外销景气优于内销。中系品牌内外市场发力,有望持续抢占市场并提升结构。展望2026年,该行认为国补政策及宏观经济仍是左右小家电内需的关键。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兴业证券:26Q2预计家电外销景气优于内销 推荐石头科技(688189.SH)等","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0224","BK0276","688169","LU2328871848.SGD","BK0214","688189","LU2488822045.USD","BK0028","601377","LU1969619763.USD","BK0012","BK0239","BK0188"],"gpt_icon":0},{"id":"2588725995","title":"南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,12月1日股价下跌2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725995?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:52","pubTimestamp":1764582777,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘,南新制药报收于9.28元,较前一交易日下跌2.01%,最新总市值为25.46亿元。公司近日发布公告称,湖南南新制药股份有限公司于2025年4月28日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购资金总额预计为1,000万元至2,000万元,用于员工持股计划或股权激励,回购价格不超过9.53元/股,回购期限为12个月。2025年11月单月回购600,841股,支付资金5,301,612.05元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100023274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2583701145","title":"南新制药前三季度亏损扩大,公司面临被监管立案等多重困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2583701145","media":"中科财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583701145?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:24","pubTimestamp":1763115840,"startTime":"0","endTime":"0","summary":"11月10日,南新制药召开2025年第三季度业绩说明会。值得注意的是,在本次业绩说明会上,南新制药并未就近一个月公司涉嫌信披违规被监管立案和公司重组事宜进行说明。同时,南新制药4.8亿元重大资产重组项目,在筹划仅一个多月后便宣告终止。业绩亏损扩大 重组终止三季报显示,南新制药第三季度营业收入为2130.81万元,环比增长0.41%。2025年9月30日晚,南新制药发布公告称,因涉嫌年报信息披露违法违规,被中国证监会立案。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxkpat1502658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688189"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773525595787,"stockEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0831},{"period":"3month","weight":-0.0411},{"period":"6month","weight":-0.3883},{"period":"1year","weight":0.2012},{"period":"ytd","weight":-0.0038}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0088},{"period":"3month","weight":0.053},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.2193},{"period":"ytd","weight":0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南南新制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14114人(较上一季度增加49.13%)","perCapita":"19441股","listingDate":"2020-03-26","address":"湖南省长沙市浏阳市经济技术开发区康里路1号","registeredCapital":"27440万元","survey":" 湖南南新制药股份有限公司的主营业务是流行性感冒等抗病毒、传染病防治药品,以及恶性肿瘤、心脑血管疾病、糖尿病等其他重大疾病治疗药品研发、生产与销售。公司的主要产品是帕拉米韦氯化钠注射液、磷酸奥司他韦干混悬剂、辛伐他汀分散片、阿托伐他汀钙片、贝那普利氢氯噻嗪片、头孢呋辛酯分散片、头孢克洛胶囊、头孢克洛干混悬剂、乳酸环丙沙星氯化钠注射液、复方布洛芬片、布洛芬混悬滴剂、布洛芬混悬液、盐酸非索非那定口服混悬液。","listedPrice":34.94},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"南新制药(688189)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供南新制药(688189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"南新制药,688189,南新制药股票,南新制药股票老虎,南新制药股票老虎国际,南新制药行情,南新制药股票行情,南新制药股价,南新制药股市,南新制药股票价格,南新制药股票交易,南新制药股票购买,南新制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"南新制药(688189)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供南新制药(688189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}